Tests presently available for detection and assay of toxins of Clostridium botulinum, when suitable for low concentration of toxin, are too slow to be practical. A more rapid assay, described by us (4) , requires far greater concentrations of toxin than are usually found in the circulation of intoxicated victims or in contaminated foods. Because of the extreme potency of botulinum toxin, an effective assay for clinical or laboratory use should be rapid, specific, and sensitive, properties that are found in the radioimmunoassay of Berson and Yalow (1) . The Berson and Yalow technique is based on competition between radiolabeled and unlabeled antigen for binding to specific antibody. As a result of this competitive binding, the ratio of bound (B) to free (F) labeled antigen, denoted as B/F, is decreased as the concentration of the unlabeled antigen increases. The concentration of the unknown sample is obtained by comparing the inhibition observed in the sample with that produced in standard solutions containing known amounts of the antigen. To be of use with the toxin, a radioimmunoassay must be performed with preparations of high purity and high specific radioactivity.
The availability of pure toxins of types A (5), B (2), D, (D. A. Boroff, and G. Shu Chen, unpublished data), and E (6) prompted investigation into the possibility of radiolabeling the toxin of C. botulinum type A and employing it in a radioimmunoassay.
MATERIALS AND METHODS
The toxin of C. botulinum type A was isolated and purified as previously described (5) . This material was homogeneous by all criteria used. Assuming a molecular weight of 150,000, 10 pg of toxin protein constituted one minimal lethal dose (MLD) to mice.
The antiserum to type A toxin was prepared in rabbits by administration of two subcutaneous injections, 20 days apart, of a Formalinized toxoid mixed with an equal amount of incomplete Freund adjuvant (3) . Twenty days after the last injection the rabbits were bled and their sera were obtained and pooled. This serum reacted with the toxin in a Ouchterlony gel double-diffusion test giving a single precipitation line.
131I was obtained from New England Nuclear Corp., Boston, Mass., in the form of potassium iodide (KI) as a carrier-free isotope with a specific activity of 123 mCi per mg of iodine. Chloramine T (ChT) was obtained from Eastman Organic Chemicals, Rochester, N.Y., sodium metabisulfite (SMBS) from J. T. Baker Chemical Co., Phillipsburg, N.J., goat antirabbit serum from Antibodies, Inc., Davis, Calif., and DE-52 cellulose from Whatman, Maidstone, Kent, England. The radioactivity was measured in a Chicago Nuclear automatic well y counter. Toxicities of the preparations were determined by intravenous mouse assay, as described elsewhere (4 concentration of toxin was mixed with KI in the presence of ChT, the concentration of the salt in the mixture and the length of exposure were critical. Table 2 shows that exposure of toxin-ChT to 40 ng of KI for as much as 30 s did not alter toxicity appreciably; when 400 mg of KI was used in the mixture, two-thirds of the toxin was inactivated within 15 s of exposure. The data in Tables 1 and 2 suggested that the toxin could be labeled if the conditions established with KI were employed using 131I as the isotope.
Accordingly, 46 jig of toxin in 100 uliters of 0.025 M Tris-hydrochloride buffer (pH 8) was combined with 25 sliters of ChT and 4.2 mg/ml and 1 mCi of 138I). The reaction was permitted to proceed for 5, 15, or 30 s before it was stopped with 100 Aliters of SMBS (5 mg/ml).
The unbound 131I was removed by adjusting the mixture with 0.5 M sodium citrate buffer to pH 5 and chromatographing it through a 1-by 25-cm column of DE-52 cellulose that was equilibrated and eluted with 0.025 M citrate buffer pH 5. The radioactive toxin (18I Tox) was eluted in the void volume. The 138I Tox was followed by a small amount of nontoxic radioactive protein which increased in amount with the length of exposure of the toxin to the isotope and finally by a large peak of unbound 181I. The eluate was collected in 3-ml portions into tubes pretreated with 0.1 ml of 2% crystalline serum albumin to prevent adherence of the toxin to the glass. From Fig. 1 it is apparent that the unbound 1811 can be entirely removed from the mixture. The best results were obtained with the exposure of the toxin to one mCi of 131I in the presence of ChT for 0.15 s (Fig. ic) . The pooled eluate of the first peak contained 3 x 107 counts per min per ml and was as toxic as the original material. The efficiency of incorporation of 138I into the toxin was calculated as 18.3%.
Since the toxin employed in the radioiodination experiment was pure, the appearance of inactive protein must be attributed to partial inactivation of the toxin in the process. The amount of this protein did not exceed 10% of the original toxin. The inability to detect the loss of toxicity is due, perhaps, to the limits of the mouse assay for the toxin employed in these experiments.
Specificity of 13II-labeled toxin. To determine whether the radioiodinated toxin retained its original specificity, samples of 13'I Tox were mixed with serially diluted antitype A botulinum rabbit serum. Each serum dilution received 2 were incubated for 30 min at 37 C. The tubes were centrifuged for 30 min at 4,000 rpm, and the radioactivities of the decanted supernatant fluid were measured. The curve (Fig. 2) , obtained by plotting radioactivity against antiserum concentration, was that of a typical antigen-antibody reaction. A strong prezone was observed in the region of antibody excess. This zone was followed by the increasing appearance of radioactivity in the precipitate until a zone of equivalence was reached, followed by a zone of increased antigen excess and the reappearance of increasing radioactivity in the supernatant fluid.
Although the inactive material observed on the elution of the 1"1I Tox from the chromatographic column could be, for the most part, separated from the toxin, the possibility that some amount of the inactive contaminant may interfere in the radioimmunoassay had to be considered. Accordingly, toxin inactivated by exposure to ChT and KI and the inactive material obtained from the column were reacted in an Ouchterlony gel double-diffusion test (Fig. 3) . Into the center of the petri plate containing 1% Noble agar (Difco) was placed anti-type A rabbit serum. The lateral wells were filled, respectively, with unlabeled toxin ("Cold" Tox), 131I (Fig. 2) .
The mixtures were incubated at 37 C for 30 min. To facilitate precipitation, 100
Tliters of 1:20 diluted normal rabbit serum and 100 pliters of 1:10 diluted goat antirabbit gamma globulin were added to each tube, and the tubes were incubated an additional 30 min at 37 C. The tubes were centrifuged at 3,000 rpm for 30 min in the cold, 200 uliters of clear supernatant fluid was withdrawn from each tube, and the radioactivity of each supernatant extract was measured. This amount of radioactivity was multiplied by a factor of 2.5 to account for the total volume of the supernatant fluid in each tube, and then the degree of radioactivity in the precipitate was calculated by subtracting the total counts per minute in the supernatant fluid from the total radioactivity of the reaction mixture before incubation. Fig. 4 , a composite of three such experiments, shows the plot obtained. This curve is typical of those obtained when the relationships of two substances in competition for a common receptor are plotted. In our case, 181I Tox and the Cold Tox competed for common receptors on the antibody molecules. Similar curves are obtained in radioimmunoassay with hormones and their respective antibodies (1) . From the curve shown in Fig. 4 , the sensitive zone of our assay would be at Cold Tox concentrations of 400 to 3,000 MLD. Within this range of toxin concentrations, the curve is practically linear and should be useful in estimating the toxin in unknown solutions.
The data presented here show that radiolabeling of type A toxin of C. botulinum is feasible and can be accomplished without significant alteration of either toxicity or immunological reactivity. The small amount of inactive protein, which was noted to separate on chromatography and which we believe to be inactivated toxin, eluted sufficiently far from the 131I Tox to be easily separated from the latter. In addition it was shown that this material does not react with antitoxic serum and, therefore, should not interfere in the radioimmunoassay.
Unpublished data suggest that the assay can be made sufficiently sensitive to detect as little as 100 MLD or 0.1 ng by increasing the antibody titer of the antiserum and by imparting higher specific radioactivity to the toxin. An added advantage may be gained if, instead of 131I with 8 days half-life, 125I of much longer (80 days) half-life is substituted, thus allowing longer use of the radiolabeled toxin.
